Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural Epublish 2 citations
PubMed: 39298171 DOI: 10.1001/jamanetworkopen.2024.34159
Acceptance of SARS-CoV-2 Surveillance Testing Among Patients Receiving Dialysis: A Cluster Randomized Trial.
JAMA Netw Open 7(9):e2434159
Authors: Maria Montez-Rath, Meri Varkila, Xue Yu, Stephanie Brillhart, Curt Morgan, Amanda Leppink, Martha S Block, Sachin Mehta, Patti Hunsader, Andrew Fountaine, Nivetha Subramanian, Mary Dittrich, Douglas K Owens, Glenn M Chertow, Julie Parsonnet, Shuchi Anand, Geoffrey A Block
Affiliations
- Department of Medicine, School of Medicine, Stanford University, Palo Alto, California.
- US Renal Care, Plano, Texas.
- Ascend Clinical Laboratory, Sunnyvale, California.
- Department of Epidemiology and Population Health, School of Medicine, Stanford University, Palo Alto, California.
Abstract
Importance
Integrating routine SARS-CoV-2 testing in dialysis facilities may benefit patients receiving dialysis by mitigating risks of serious illness and reducing transmission. Patient acceptance of nonmandatory testing is unknown.
Objective
To evaluate the acceptance of 2 SARS-CoV-2 testing strategies among patients in hemodialysis facilities nationwide.
Design, Setting, and Participants
This nationwide cluster (dialysis facility-level) randomized trial investigated the acceptance of SARS-CoV-2 testing among patients receiving maintenance hemodialysis at facilities located in 22 states.
Intervention
Anterior nares real-time reverse transcriptase-polymerase chain reaction tests offered once every 2 weeks (static testing facilities) vs offered once a week, once every 2 weeks, or once a month depending on county COVID-19 infection prevalence (dynamic testing facilities). Facilities were randomized by county, and tests were offered for 3 months between February 4 and July 24, 2023.
Main Outcomes and Measures
The primary outcome was test acceptance. Secondary outcomes included the proportion of patients who accepted at least 1 test.
Results
In total, 62 hemodialysis facilities were randomized and 57 participated. Among 2389 participating patients, the median age was 64 (IQR, 54-74) years, 1341 (56%) were male, 138 (6%) were categorized as American Indian, 60 (3%) Asian, 885 (37%) Black, 75 (3%) Native Hawaiian or Pacific Islander, 338 (14%) Hispanic, and 876 (37%) White; and 1603 (67%) had diabetes. A median of 6 (IQR, 6-6) tests were offered per patient in the static arm and 4 (3-6) tests in the dynamic arm. Test acceptance was low: 8% of offered tests were accepted in each of the test arms. Among 503 patients who accepted at least 1 test, the median percentage of offered tests that were accepted was 16% (IQR, 17%-42%) using the static testing strategy and 50% (IQR, 33%-75%) using the dynamic testing strategy (P < .001). Older patients (odds ratio [OR], 1.08 [95% CI, 1.01-1.16] per 5-year age increment), patients with (vs without) diabetes (OR, 1.59 [95% CI, 1.18-2.16]), and women compared with men (OR, 1.30 [95% CI, 0.98-1.73]) were more likely to accept multiple tests. Patients designated in the electronic health record as Hispanic were more likely than patients designated as White (OR, 1.78 [95% CI, 1.15-2.76]) to accept at least 1 test, whereas patients living in zip codes electing Republican representatives to Congress were less likely than patients living in zip codes electing Democratic representatives (OR, 0.34 [95% CI, 0.17-0.69]) to accept multiple tests.
Conclusions and Relevance
In this cluster randomized trial evaluating 2 SARS-CoV-2 testing strategies in dialysis facilities, test acceptance was low, and a dynamic testing strategy anchored to COVID-19 infection prevalence did not outperform a static testing strategy of every 2 weeks.
Trial Registration
ClinicalTrials.gov Identifier: NCT05225298.
MeSH
Diabetes Mellitus, Research Design, Sars-Cov-2, Clinical Medicine, Prevalence, Severe Acute Respiratory Syndrome-Related Coronavirus, Infections